Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARGlu-NMO: Slow vs Rapid Glucocorticoid Tapering with Inebilizumab in NMOSD
NCT07132398Phase 3Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07132398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132398.